Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

78 results about "Serotonin transporter" patented technology

The serotonin transporter (SERT or 5-HTT) also known as the sodium-dependent serotonin transporter and solute carrier family 6 member 4 is a protein that in humans is encoded by the SLC6A4 gene. SERT is a type of monoamine transporter protein that transports serotonin from the synaptic cleft back to the presynaptic neuron.

Organic compounds

ActiveUS20170183350A1To promote metabolismImproves in vitro hepatic microsome stabilityOrganic active ingredientsNervous disorderDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC

Serotonin transporter gene and treament of alcoholism

ActiveUS20110112159A1Physical improvementImproving psychological sequelaOrganic active ingredientsBiocideDiseaseAlcoholisms
The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs 1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Organic compounds

ActiveUS20190231780A1Avoid side effectsInhibit the serotonin re-uptake transporterOrganic active ingredientsNervous disorderDisease5-HT4 receptor
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC

Methods for managing care of patients predisposed to progressive mitral valve diseases

The present invention relates to methods for treating or preventing a mitral valve disease in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic agent. The therapeutic agent is capable of suppressing serotonin receptor signaling. The methods may be combined with a mitral valve surgery, serotonin transporter polymorphism genotyping, MV disease diagnosis, and / or an adjunct assay. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Serotonin transporter gene and treatment of alcoholism

The gene (SLC6A4) responsible for encoding the serotonin transporter (SERT) has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on diagnosing variations in the polymorphisms of the SERT gene and expression and activity of the SERT gene, as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders, for monitoring treatment and / or abuse (addictive behavior), and for determining which treatment should be used.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through PKG/p38 map kinase

The invention relates to the observation that the p38 mitogen-activated protein kinase pathway is an important regulator of biogenic amine transporter (BAT) function. By using modulator of p38 MAPK, one can alter BAT function in a specific manner. This recognition of the pathway and its interaction with the serotonin transporter (SERT) and the norepinephrine transporter (NET), along with the PPA, PKG and PDE pathways, also provides the opportunity to identify polymorphisms that will impact the efficacy of drugs that act though on these enzymes or their pathways.
Owner:VANDERBILT UNIV

Organic compounds

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC

A3 adenosine receptors as targets for the modulation of central serotonergic signaling

InactiveUS20090088403A1Reducing SERT activityEnhance SERT activityBiocideCarbohydrate active ingredientsSerotonin transporterIn vivo
The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants.
Owner:VANDERBILT UNIV

Genetic screening for predicting antidepressant drug response based on the monoamine transporter gene polymorphism combination

InactiveUS20080248470A1Microbiological testing/measurementNoradrenaline reuptake inhibitorBiology
The present invention discloses is a method of selecting a drug based on personal genetic information when prescribing an antidepressant for a depressed patient. According to the invention, either a noradrenaline reuptake inhibitor (NRI) antidepressant or a selective serotonin reuptake inhibitor (SSRI) antidepressant can be selected based on the combination of monoamine transporter gene polymorphisms, that is, NET G1287A polymorphism in a norepinephrine transporter (NET) gene, serotonin transporter gene (5-HTT) promoter polymorphism and 5-HTT gene intron 2 polymorphism. Also, based on the norepinephrine transporter gene NET G1287A polymorphism alone, the noradrenaline reuptake inhibitor (NRI) antidepressant can be selected.
Owner:RES & BUSINESS FOUND SUNGKYUNKWAN UNIV

Tropane derivatives useable in particular for in vivo detection of dopamine transporters

The present invention relates to tropane derivatives having particular use for the in vivo detection of dopamine transporters.These derivatives meet the formulain which R1 is I or Sn (R3)3, R2 is for example the methyl group, and X and Y are various substituents.The derivatives with X=CH3 and Y=H show strong specificity for the dopamine transporter compared with the serotonin transporter (74% inhibition when the transporter is previously saturated with GBR 12909).
Owner:CIS BIO INT

Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
Owner:NLIFE THERAPEUTICS

Gene polymorphism useful for assistance/therapy for smoking cessation

Disclosed is a method for determination of a smoking trend in a subject which is useful for the assistance or therapy for smoking cessation, which comprises the steps of detecting one or more polymorphisms occurring on one or more genes selected from the genes (1) to (3) or a genome or in the neighborhood of the genes or the genome and determining the smoking trend based on the results of the detection: (1) nicotinic acetylcholine receptor β2 subunit (CHRNB2) gene; (2) serotonin transporter (SLC6A4(5HTT)) gene; and (3) nicotinic acetylcholine receptor α4 subunit (CHRNA4) gene.
Owner:OSAKA UNIV +1

Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Calamus amide compound as well as preparation method and application of calamus amide compound

The invention provides a calamus amide compound as well as a preparation method and application of the calamus amide compound. The compound is (E)-methyl- 4-[3-(4-hydroxy-3-methoxyphenyl)acrylamido]butanoate or a (Z)-methyl- 4-[3-(4-hydroxy-3-methoxyphenyl)acrylamido]butanoate enol isomer, is separated and purified from roots and stems of acorus tatarinowii serving as an araceae acorus plant, has the effect of promoting the activity of a 5-serotonin transporter (SERT), can be used as a drug for treating depressive disorder, anxiety disorder, schizophrenia, obsession, neurodegenerative diseases, drug addiction or digestive system dysfunction and other diseases, and has an important drug development value.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Organic compounds

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and / or the μ-opioid receptor.
Owner:INTRA CELLULAR THERAPIES INC

Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety

The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and / or in the treatment of anxiety.
Owner:F HOFFMANN LA ROCHE & CO AG

Boat tropanes

Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
Owner:ORGANIX +2

Compounds acting on the serotonin transporter

InactiveUS20100048713A1Conducive to survival and growthEasy to learnBiocideHalogenated hydrocarbon active ingredientsDiseasePanic
The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.
Owner:AARHUS UNIV +1

Pharmaceutical, food or beverage having inhibitory activity on serotonin transporter

There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid.
Owner:SUNTORY HLDG LTD

System for treating addictions

InactiveUS20080226759A1Feel goodOptimize way mood elevation is achievedBiocidePeptide/protein ingredientsRegimenPhysiology
A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive / addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient. The system further includes individual and group counseling and initial oxygen therapy. The genetic testing assesses the presence of gene polymorphism in at least one of D2 dopamine receptor gene (DRD2), dopamine transporter gene (DAT1), dopamine beta-hydroxylase gene (DBH) and serotonin transporter (SERT) gene. The dietary supplements are tailored to stimulate production of neuromediators or neurotransmitters, depending upon the polymorphism determined. The exercises include static and dynamic routines also tailored to the results of the genetic testing. After completion of the inpatient portion of the system, further therapies include daily exercise and dietary supplement programs tailored for each polymorphism discovered.
Owner:MARSHAK YAKOV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products